RapamycinFungusV1, Main, Exploration, bibRecord, 000B15

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Identifieur interne : 000B15 ( Main/Exploration ); précédent : 000B14; suivant : 000B16

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Auteurs : Carlos Cervera [Canada, Espagne] ; Frederic Cofan [Espagne] ; Cristina Hernandez [Canada] ; Dolors Soy [Espagne] ; Maria Angeles Marcos [Espagne] ; Gemma Sanclemente [Canada] ; Marta Bodro [Canada] ; Asunci N Moreno [Canada] ; Fritz Diekmann [Espagne] ; Josep Maria Campistol [Espagne] ; Frederic Oppenheimer [Espagne]

Source :

Transplant international : official journal of the European Society for Organ Transplantation [ 1432-2277 ] ; 2016.

RBID : pubmed:27564469

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse multifactorielle (MeSH), Espagne (MeSH), Femelle (MeSH), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Immunosuppression thérapeutique (MeSH), Infections à cytomégalovirus (prévention et contrôle), Infections à cytomégalovirus (traitement médicamenteux), Inhibiteurs de la calcineurine (usage thérapeutique), Insuffisance rénale (chirurgie), Modèles des risques proportionnels (MeSH), Mâle (MeSH), Risque (MeSH), Score de propension (MeSH), Sirolimus (usage thérapeutique), Sujet âgé (MeSH), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérum antilymphocyte (usage thérapeutique), Transplantation rénale (MeSH), Études rétrospectives (MeSH).
MESH :
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- chirurgie : Insuffisance rénale.
- prévention et contrôle : Infections à cytomégalovirus.
- traitement médicamenteux : Infections à cytomégalovirus.
- usage thérapeutique : Immunosuppresseurs, Inhibiteurs de la calcineurine, Sirolimus, Sérum antilymphocyte.
- Adulte, Adulte d'âge moyen, Analyse multifactorielle, Espagne, Femelle, Humains, Immunosuppression thérapeutique, Modèles des risques proportionnels, Mâle, Risque, Score de propension, Sujet âgé, Transplantation rénale, Études rétrospectives.

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Antilymphocyte Serum (therapeutic use), Calcineurin Inhibitors (therapeutic use), Cytomegalovirus Infections (drug therapy), Cytomegalovirus Infections (prevention & control), Female (MeSH), Humans (MeSH), Immunosuppression (MeSH), Immunosuppressive Agents (therapeutic use), Kidney Transplantation (MeSH), Male (MeSH), Middle Aged (MeSH), Multivariate Analysis (MeSH), Propensity Score (MeSH), Proportional Hazards Models (MeSH), Renal Insufficiency (surgery), Retrospective Studies (MeSH), Risk (MeSH), Sirolimus (therapeutic use), Spain (MeSH), TOR Serine-Threonine Kinases (antagonists & inhibitors).
MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , therapeutic use : Antilymphocyte Serum, Calcineurin Inhibitors, Immunosuppressive Agents, Sirolimus.
- drug therapy : Cytomegalovirus Infections.
- prevention & control : Cytomegalovirus Infections.
- surgery : Renal Insufficiency.
- Adult, Aged, Female, Humans, Immunosuppression, Kidney Transplantation, Male, Middle Aged, Multivariate Analysis, Propensity Score, Proportional Hazards Models, Retrospective Studies, Risk, Spain.

Abstract

Mammalian target of rapamycin inhibitors (mTORi) prevents cytomegalovirus (CMV) infection in kidney transplant (KT) patients. From May 2010 to December 2013, all KT recipients were retrospectively analysed. Maintenance immunosuppression regimen was divided into mTORi or calcineurin inhibitors (CNI)-based regimen. Since June 2011, CMV-seropositive recipients (R+) treated with high-intensity immunosuppression and mTORi did not receive anti-CMV prophylaxis. We analysed 350 consecutive patients, of which 95 (27%) received mTORi and 255 (73%) CNI-based immunosuppression. A Cox-regression multivariate analysis showed that the use of mTORi-based immunosuppression during all follow-up reduced the risk of CMV infection (HR 0.36, 95% CI 0.15-0.89, P = 0.028) and confirmed in a propensity score-matched cohort (HR 0.4, 95% CI 0.1-0.9, P = 0.047). Early discontinuation of mTORi increased the risk of CMV infection (HR 3.2; 95% CI 1.7-6.0) in univariate analysis. The incidence of CMV infection was not higher among CMV R+ patients on mTORi and requiring high-intensity immunosuppression when CMV prophylaxis was not given. The use of mTORi protected for CMV infection in KT patients, allowing to avoid antiviral prophylaxis for R+ patients receiving high-intensity immunosuppression. The increased risk of CMV infection after early discontinuation of mTORi warrants further research.

DOI: 10.1111/tri.12848
PubMed: 27564469

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000945
to stream Main, to step Curation: 000945

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.</title>
<author><name sortKey="Cervera, Carlos" sort="Cervera, Carlos" uniqKey="Cervera C" first="Carlos" last="Cervera">Carlos Cervera</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada. cerveraa@ualberta.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain. cerveraa@ualberta.ca.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Infectious Diseases, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cofan, Frederic" sort="Cofan, Frederic" uniqKey="Cofan F" first="Frederic" last="Cofan">Frederic Cofan</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hernandez, Cristina" sort="Hernandez, Cristina" uniqKey="Hernandez C" first="Cristina" last="Hernandez">Cristina Hernandez</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Soy, Dolors" sort="Soy, Dolors" uniqKey="Soy D" first="Dolors" last="Soy">Dolors Soy</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Pharmacy, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Pharmacy, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcos, Maria Angeles" sort="Marcos, Maria Angeles" uniqKey="Marcos M" first="Maria Angeles" last="Marcos">Maria Angeles Marcos</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Microbiology, Centre Diagnòstic Biomèdic (CDB), Centre for International Health Research (CRESIB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Microbiology, Centre Diagnòstic Biomèdic (CDB), Centre for International Health Research (CRESIB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanclemente, Gemma" sort="Sanclemente, Gemma" uniqKey="Sanclemente G" first="Gemma" last="Sanclemente">Gemma Sanclemente</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bodro, Marta" sort="Bodro, Marta" uniqKey="Bodro M" first="Marta" last="Bodro">Marta Bodro</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Diekmann, Fritz" sort="Diekmann, Fritz" uniqKey="Diekmann F" first="Fritz" last="Diekmann">Fritz Diekmann</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Campistol, Josep Maria" sort="Campistol, Josep Maria" uniqKey="Campistol J" first="Josep Maria" last="Campistol">Josep Maria Campistol</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oppenheimer, Frederic" sort="Oppenheimer, Frederic" uniqKey="Oppenheimer F" first="Frederic" last="Oppenheimer">Frederic Oppenheimer</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27564469</idno>
<idno type="pmid">27564469</idno>
<idno type="doi">10.1111/tri.12848</idno>
<idno type="wicri:Area/Main/Corpus">000945</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000945</idno>
<idno type="wicri:Area/Main/Curation">000945</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000945</idno>
<idno type="wicri:Area/Main/Exploration">000945</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.</title>
<author><name sortKey="Cervera, Carlos" sort="Cervera, Carlos" uniqKey="Cervera C" first="Carlos" last="Cervera">Carlos Cervera</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada. cerveraa@ualberta.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain. cerveraa@ualberta.ca.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Infectious Diseases, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cofan, Frederic" sort="Cofan, Frederic" uniqKey="Cofan F" first="Frederic" last="Cofan">Frederic Cofan</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hernandez, Cristina" sort="Hernandez, Cristina" uniqKey="Hernandez C" first="Cristina" last="Hernandez">Cristina Hernandez</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Soy, Dolors" sort="Soy, Dolors" uniqKey="Soy D" first="Dolors" last="Soy">Dolors Soy</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Pharmacy, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Pharmacy, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marcos, Maria Angeles" sort="Marcos, Maria Angeles" uniqKey="Marcos M" first="Maria Angeles" last="Marcos">Maria Angeles Marcos</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Microbiology, Centre Diagnòstic Biomèdic (CDB), Centre for International Health Research (CRESIB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Division of Microbiology, Centre Diagnòstic Biomèdic (CDB), Centre for International Health Research (CRESIB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanclemente, Gemma" sort="Sanclemente, Gemma" uniqKey="Sanclemente G" first="Gemma" last="Sanclemente">Gemma Sanclemente</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bodro, Marta" sort="Bodro, Marta" uniqKey="Bodro M" first="Marta" last="Bodro">Marta Bodro</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Diekmann, Fritz" sort="Diekmann, Fritz" uniqKey="Diekmann F" first="Fritz" last="Diekmann">Fritz Diekmann</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Campistol, Josep Maria" sort="Campistol, Josep Maria" uniqKey="Campistol J" first="Josep Maria" last="Campistol">Josep Maria Campistol</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oppenheimer, Frederic" sort="Oppenheimer, Frederic" uniqKey="Oppenheimer F" first="Frederic" last="Oppenheimer">Frederic Oppenheimer</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Transplant international : official journal of the European Society for Organ Transplantation</title>
<idno type="eISSN">1432-2277</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Antilymphocyte Serum (therapeutic use)</term>
<term>Calcineurin Inhibitors (therapeutic use)</term>
<term>Cytomegalovirus Infections (drug therapy)</term>
<term>Cytomegalovirus Infections (prevention & control)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppression (MeSH)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Kidney Transplantation (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Multivariate Analysis (MeSH)</term>
<term>Propensity Score (MeSH)</term>
<term>Proportional Hazards Models (MeSH)</term>
<term>Renal Insufficiency (surgery)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Risk (MeSH)</term>
<term>Sirolimus (therapeutic use)</term>
<term>Spain (MeSH)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse multifactorielle (MeSH)</term>
<term>Espagne (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Immunosuppression thérapeutique (MeSH)</term>
<term>Infections à cytomégalovirus (prévention et contrôle)</term>
<term>Infections à cytomégalovirus (traitement médicamenteux)</term>
<term>Inhibiteurs de la calcineurine (usage thérapeutique)</term>
<term>Insuffisance rénale (chirurgie)</term>
<term>Modèles des risques proportionnels (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Risque (MeSH)</term>
<term>Score de propension (MeSH)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérum antilymphocyte (usage thérapeutique)</term>
<term>Transplantation rénale (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antilymphocyte Serum</term>
<term>Calcineurin Inhibitors</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Insuffisance rénale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cytomegalovirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cytomegalovirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à cytomégalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Renal Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à cytomégalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunosuppresseurs</term>
<term>Inhibiteurs de la calcineurine</term>
<term>Sirolimus</term>
<term>Sérum antilymphocyte</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Immunosuppression</term>
<term>Kidney Transplantation</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Propensity Score</term>
<term>Proportional Hazards Models</term>
<term>Retrospective Studies</term>
<term>Risk</term>
<term>Spain</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse multifactorielle</term>
<term>Espagne</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunosuppression thérapeutique</term>
<term>Modèles des risques proportionnels</term>
<term>Mâle</term>
<term>Risque</term>
<term>Score de propension</term>
<term>Sujet âgé</term>
<term>Transplantation rénale</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mammalian target of rapamycin inhibitors (mTORi) prevents cytomegalovirus (CMV) infection in kidney transplant (KT) patients. From May 2010 to December 2013, all KT recipients were retrospectively analysed. Maintenance immunosuppression regimen was divided into mTORi or calcineurin inhibitors (CNI)-based regimen. Since June 2011, CMV-seropositive recipients (R+) treated with high-intensity immunosuppression and mTORi did not receive anti-CMV prophylaxis. We analysed 350 consecutive patients, of which 95 (27%) received mTORi and 255 (73%) CNI-based immunosuppression. A Cox-regression multivariate analysis showed that the use of mTORi-based immunosuppression during all follow-up reduced the risk of CMV infection (HR 0.36, 95% CI 0.15-0.89, P = 0.028) and confirmed in a propensity score-matched cohort (HR 0.4, 95% CI 0.1-0.9, P = 0.047). Early discontinuation of mTORi increased the risk of CMV infection (HR 3.2; 95% CI 1.7-6.0) in univariate analysis. The incidence of CMV infection was not higher among CMV R+ patients on mTORi and requiring high-intensity immunosuppression when CMV prophylaxis was not given. The use of mTORi protected for CMV infection in KT patients, allowing to avoid antiviral prophylaxis for R+ patients receiving high-intensity immunosuppression. The increased risk of CMV infection after early discontinuation of mTORi warrants further research.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27564469</PMID>
<DateCompleted><Year>2017</Year>
<Month>08</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>08</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2277</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>11</Issue>
<PubDate><Year>2016</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Transplant international : official journal of the European Society for Organ Transplantation</Title>
<ISOAbbreviation>Transpl Int</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.</ArticleTitle>
<Pagination><MedlinePgn>1216-1225</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/tri.12848</ELocationID>
<Abstract><AbstractText>Mammalian target of rapamycin inhibitors (mTORi) prevents cytomegalovirus (CMV) infection in kidney transplant (KT) patients. From May 2010 to December 2013, all KT recipients were retrospectively analysed. Maintenance immunosuppression regimen was divided into mTORi or calcineurin inhibitors (CNI)-based regimen. Since June 2011, CMV-seropositive recipients (R+) treated with high-intensity immunosuppression and mTORi did not receive anti-CMV prophylaxis. We analysed 350 consecutive patients, of which 95 (27%) received mTORi and 255 (73%) CNI-based immunosuppression. A Cox-regression multivariate analysis showed that the use of mTORi-based immunosuppression during all follow-up reduced the risk of CMV infection (HR 0.36, 95% CI 0.15-0.89, P = 0.028) and confirmed in a propensity score-matched cohort (HR 0.4, 95% CI 0.1-0.9, P = 0.047). Early discontinuation of mTORi increased the risk of CMV infection (HR 3.2; 95% CI 1.7-6.0) in univariate analysis. The incidence of CMV infection was not higher among CMV R+ patients on mTORi and requiring high-intensity immunosuppression when CMV prophylaxis was not given. The use of mTORi protected for CMV infection in KT patients, allowing to avoid antiviral prophylaxis for R+ patients receiving high-intensity immunosuppression. The increased risk of CMV infection after early discontinuation of mTORi warrants further research.</AbstractText>
<CopyrightInformation>© 2016 Steunstichting ESOT.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cervera</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada. cerveraa@ualberta.ca.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain. cerveraa@ualberta.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cofan</LastName>
<ForeName>Frederic</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hernandez</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Soy</LastName>
<ForeName>Dolors</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacy, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marcos</LastName>
<ForeName>Maria Angeles</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Division of Microbiology, Centre Diagnòstic Biomèdic (CDB), Centre for International Health Research (CRESIB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sanclemente</LastName>
<ForeName>Gemma</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bodro</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moreno</LastName>
<ForeName>Asunción</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Diekmann</LastName>
<ForeName>Fritz</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Campistol</LastName>
<ForeName>Josep Maria</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oppenheimer</LastName>
<ForeName>Frederic</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Renal Transplantation Unit, Division of Nephrology, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>09</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Transpl Int</MedlineTA>
<NlmUniqueID>8908516</NlmUniqueID>
<ISSNLinking>0934-0874</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000961">Antilymphocyte Serum</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000961" MajorTopicYN="N">Antilymphocyte Serum</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytomegalovirus</Keyword>
<Keyword MajorTopicYN="N">kidney transplantation</Keyword>
<Keyword MajorTopicYN="N">mammalian target of rapamycin inhibitors</Keyword>
<Keyword MajorTopicYN="N">polyclonal anti-lymphocyte globulins</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>05</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>05</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>08</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27564469</ArticleId>
<ArticleId IdType="doi">10.1111/tri.12848</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>Espagne</li>
</country>
<region><li>Catalogne</li>
</region>
<settlement><li>Barcelone</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Cervera, Carlos" sort="Cervera, Carlos" uniqKey="Cervera C" first="Carlos" last="Cervera">Carlos Cervera</name>
</noRegion>
<name sortKey="Bodro, Marta" sort="Bodro, Marta" uniqKey="Bodro M" first="Marta" last="Bodro">Marta Bodro</name>
<name sortKey="Hernandez, Cristina" sort="Hernandez, Cristina" uniqKey="Hernandez C" first="Cristina" last="Hernandez">Cristina Hernandez</name>
<name sortKey="Moreno, Asunci N" sort="Moreno, Asunci N" uniqKey="Moreno A" first="Asunci N" last="Moreno">Asunci N Moreno</name>
<name sortKey="Sanclemente, Gemma" sort="Sanclemente, Gemma" uniqKey="Sanclemente G" first="Gemma" last="Sanclemente">Gemma Sanclemente</name>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Cervera, Carlos" sort="Cervera, Carlos" uniqKey="Cervera C" first="Carlos" last="Cervera">Carlos Cervera</name>
</region>
<name sortKey="Campistol, Josep Maria" sort="Campistol, Josep Maria" uniqKey="Campistol J" first="Josep Maria" last="Campistol">Josep Maria Campistol</name>
<name sortKey="Cofan, Frederic" sort="Cofan, Frederic" uniqKey="Cofan F" first="Frederic" last="Cofan">Frederic Cofan</name>
<name sortKey="Diekmann, Fritz" sort="Diekmann, Fritz" uniqKey="Diekmann F" first="Fritz" last="Diekmann">Fritz Diekmann</name>
<name sortKey="Marcos, Maria Angeles" sort="Marcos, Maria Angeles" uniqKey="Marcos M" first="Maria Angeles" last="Marcos">Maria Angeles Marcos</name>
<name sortKey="Oppenheimer, Frederic" sort="Oppenheimer, Frederic" uniqKey="Oppenheimer F" first="Frederic" last="Oppenheimer">Frederic Oppenheimer</name>
<name sortKey="Soy, Dolors" sort="Soy, Dolors" uniqKey="Soy D" first="Dolors" last="Soy">Dolors Soy</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B15 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B15 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27564469
   |texte=   Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27564469" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki